ISORAY, INC. (NYSEMKT:ISR) Files An 8-K Other Events
Item8.01.
| Other Events. |
On March 9, 2017, IsoRay, Inc. (the Company) issued a press
release announcing that the previously announced Stipulation of
Settlement, to which IsoRay and Dwight Babcock (IsoRays former
CEO) agreed to settle the consolidated securities class action
litigation, In re IsoRay, Inc. Securities Litigation, Case No.
4:15-cv-05046-LRS, has been approved by the U.S. District Court
for the Eastern District of Washington. Attached hereto as
Exhibit 99.1 is such press release.
The information in this Current Report on Form 8-K, including the
exhibit, is furnished to Item8.01 and shall not be deemed filed
for the purposes of Section18 of the Securities Exchange Act of
1934, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, except as shall be
expressly set forth by specific reference in such filing.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit | Description | |
| 99.1 | Press release issued by IsoRay, Inc., dated March 9, 2017. |
About ISORAY, INC. (NYSEMKT:ISR)
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company’s Proxcelan Cesium-131 seed is classified as a Class II device. ISORAY, INC. (NYSEMKT:ISR) Recent Trading Information
ISORAY, INC. (NYSEMKT:ISR) closed its last trading session down -0.020 at 0.510 with 175,888 shares trading hands.